NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Ipratropium

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

A short-acting muscarinic antagonist (SAMA/short-acting anticholinergic) used for the maintenance treatment of COPD and as an adjunct to beta-agonists in acute severe asthma and COPD exacerbations. The nebulized form (often combined with albuterol as DuoNeb/Combivent) is a standard component of acute bronchospasm management in emergency departments. The nasal spray formulation (Atrovent Nasal) treats rhinorrhea associated with allergic and nonallergic rhinitis and the common cold.

Evidence tier
Strong
Indexed sources
10 1995–2025
Interactions
0
Category
Prescription
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

A short-acting muscarinic antagonist (SAMA/short-acting anticholinergic) used for the maintenance treatment of COPD and as an adjunct to beta-agonists in acute severe asthma and COPD exacerbations. NutriStack rates the supporting evidence as strong. Common adult dosing is MDI: 2 puffs (17 mcg each) QID; nebulizer: 500 mcg every 6-8 hours; nasal spray: 2 sprays (42 mcg) per nostril BID-TID; acute exacerbation: 500 mcg nebulized every 20 min x 3 doses with albuterol (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.

What it's good for
  • Maintenance bronchodilation in COPD8
  • Adjunct to albuterol in acute severe asthma exacerbations2,3
  • Combined with albuterol (Combivent/DuoNeb) for COPD1,2
  • Treats rhinorrhea (nasal spray formulation)
  • Useful when beta-agonists are contraindicated (cardiac patients)
What to watch for
  • Dry mouth
  • Cough
  • Headache
  • Known hypersensitivity to ipratropium, atropine, or atropine derivatives1,2
  • Known hypersensitivity to soy lecithin or related food products (MDI formulation)

The bottom line

Evidence rating strong. Most-documented uses: maintenance bronchodilation in copd, adjunct to albuterol in acute severe asthma exacerbations, combined with albuterol (combivent/duoneb) for copd. 10 sources indexed (1995–2025), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

A quaternary ammonium derivative of atropine that competitively blocks muscarinic M1, M2, and M3 receptors in bronchial smooth muscle and submucosal glands. Blockade of parasympathetic vagal tone reduces basal bronchomotor tone and inhibits reflex bronchoconstriction. Also decreases mucus secretion from goblet cells and submucosal glands. Unlike tiotropium, ipratropium has relatively equal affinity for all muscarinic subtypes and shorter receptor binding duration, requiring more frequent dosing.

Class
Short-Acting Muscarinic Antagonist (SAMA)
Dosing

Dosing & protocol.

Common range
MDI: 2 puffs (17 mcg each) QID; nebulizer: 500 mcg every 6-8 hours; nasal spray: 2 sprays (42 mcg) per nostril BID-TID; acute exacerbation: 500 mcg nebulized every 20 min x 3 doses with albuterol (as prescribed by your physician)
Recommended form
Metered-dose inhaler (MDI), nebulizer solution, or nasal spray

Delivered by inhalation or nasal spray. Poorly absorbed systemically (<2% bioavailability) due to quaternary ammonium structure. Local bronchodilator effect with minimal systemic anticholinergic effects.2

Safety

Full safety detail.

Side effects

  • Dry mouth
  • Cough
  • Headache
  • Nausea
  • Dizziness
  • Blurred vision (if sprayed into eyes)
  • Urinary retention (rare)

Contraindications

  • Known hypersensitivity to ipratropium, atropine, or atropine derivatives1,2
  • Known hypersensitivity to soy lecithin or related food products (MDI formulation)
  • Not for primary treatment of acute bronchospasm alone (use with SABA)2,3
  • Narrow-angle glaucoma (protect eyes during nebulizer use)
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5

Randomized controlled trials

1

Reference material

4
FAQ

Common questions.

Quick answers about Ipratropium, drawn from the data on this page.

What is Ipratropium?

A short-acting muscarinic antagonist (SAMA/short-acting anticholinergic) used for the maintenance treatment of COPD and as an adjunct to beta-agonists in acute severe asthma and COPD exacerbations. The nebulized form (often combined with albuterol as DuoNeb/Combivent) is a standard component of acute bronchospasm management in emergency departments. The nasal spray formulation (Atrovent Nasal) treats rhinorrhea associated with allergic and nonallergic rhinitis and the common cold.

What is Ipratropium used for?

Commonly cited benefits of Ipratropium include: Maintenance bronchodilation in COPD; Adjunct to albuterol in acute severe asthma exacerbations; Combined with albuterol (Combivent/DuoNeb) for COPD; Treats rhinorrhea (nasal spray formulation); Useful when beta-agonists are contraindicated (cardiac patients). NutriStack rates the overall evidence as strong.

What is a typical dose of Ipratropium?

A typical adult dose of Ipratropium is MDI: 2 puffs (17 mcg each) QID; nebulizer: 500 mcg every 6-8 hours; nasal spray: 2 sprays (42 mcg) per nostril BID-TID; acute exacerbation: 500 mcg nebulized every 20 min x 3 doses with albuterol (as prescribed by your physician). The commonly recommended form is Metered-dose inhaler (MDI), nebulizer solution, or nasal spray. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Ipratropium?

Reported side effects include dry mouth, cough, headache, nausea, dizziness, blurred vision (if sprayed into eyes). This is educational information; check with a healthcare professional before use.

How strong is the evidence for Ipratropium?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Ipratropium in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.